Renalys Pharma Announces Positive Phase III Results for Sparsentan in Japanese IgA Nephropathy Patients
- January 1, 2026
Gilead’s Dual-Action HIV Breakthrough: Single-Tablet Bictegravir-Lenacapavir Regimen Shows Promise in Phase 3 Trial
FDA Approves Enhertu Combination for First-Line HER2-Positive Breast Cancer
GLP-1 Drugs Show Promise in Lowering Epilepsy Risk Among Diabetes Patients
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Renalys Pharma has announced strong results in a recent Phase III study in Japan, showing positive effects on IgAN patients treated with sparsentan. Read more here:
patientworthy.com/2026/01/01/renalys-pharma-announces-positive-phase-iii-results-for-sparsentan-i...
Happy New Year from Patient Worthy! As we step into 2026, we're grateful for our incredible community and excited about the impact we'll create together. Here's to new beginnings, shared stories, and endless hope. #HappyNewYear #PatientWorthy
The holidays can stir up many emotions: joy, nostalgia, and sometimes heartache.
If you’re missing someone this season or feeling the weight of what’s changed, know that it’s okay to slow down, protect your peace, and do the holidays your way.
Not every tradition has to stay the same. Sometimes healing looks like creating new ones, honoring old ones quietly, or simply making space to rest.
#ChronicIllnessCommunity #RareDiseaseWarrior #CancerAwareness #ShareYourStory #PatientWorthy
